Log In
BCIQ
Print this Print this
 

Simponi Aria, golimumab (IV Simponi golimumab)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionIV formulation of subcutaneous Simponi, a mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$500.0M

$500.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/05/2009

$500.0M

$500.0M

0

Get a free BioCentury trial today